Aurora Cannabis Announces Fiscal 2027 Second Quarter Results
Aurora Cannabis reported fiscal Q2 2027 net revenue of $86.0 million, up 9% YoY, anchored by record international medical cannabis revenue of $61.4 million, up 44% on German and Polish patient demand. The quarter was mixed beneath the headline: Canadian medical revenue fell 24% to $21.2 million on federal reimbursement changes, adjusted EBITDA slipped to $14.0 million from $15.4 million, and free cash flow remained an outflow at $17.5 million, though improved by $22.4 million year-over-year. Aurora carries $133.0 million of cash and short-term investments with no debt.
Key figures
- Revenue
- $86.0 million
- Revenue Yoy
- 9%
- Free cash flow
- -$17.5 million
- Adjusted ebitda
- $14.0 million
- Adjusted net income
- $3.1 million
- Adjusted gross margin
- 61%
- Acquisition cash option
- C$7.80 per share
- Acquisition mixed option
- C$3.75 cash plus 3.0431 Organigram shares
- Acquisition share option
- 5.8626 Organigram shares per Aurora share
- Canadian medical net revenue
- $21.2 million
- Canadian medical revenue yoy
- -24%
- Net loss continuing operations
- $21.1 million
- Cash and short term investments
- $133.0 million
- International medical net revenue
- $61.4 million
- International medical revenue yoy
- 44%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.